AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9332329
Drug: Conventional amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional amphotericin B 1 mg/kg/d (c‐AMB)
Trial: 9332329
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B 1 mg/kg/d (L‐AMB1)
Trial: 9332329
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B 3 mg/kg/d (L‐AMB3)
Trial: 8229130
Drug: Discontinued exogenous
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued exogenous endocrine therapy
Trial: 3094063
Drug: Ethanol (EtOH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol (EtOH) 0.33 ml/kg
Trial: 3094063
Drug: Ethanol (EtOH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol (EtOH) 1.0 ml/kg
Trial: 30903329
Drug: 800 ml
RxNorm normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 ml PEG + Asc (Regimen A)
Trial: 30903329
Drug: 600 ml
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 ml PEG + Asc (Regimen B)
Trial: 30903329
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml PEG + Asc (Regimen C)
Trial: 21714641
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (CT) screening
Trial: 15286133
Drug: Therapies directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies directed at correcting demineralization-remineralization imbalance
Trial: 11217014
Drug: Zolpidem-induced sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem-induced sleep (10 mg)
Trial: 8486328
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (SB) 250 mg
Trial: 8486328
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (SB) 1,000 mg
Trial: 24162462
Drug: Emulsified isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emulsified isoflurane (EI) at doses starting from 0.3 mg/kg to 64.6 mg/kg
Trial: 20299628
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 500 microg bid + active theophylline capsules (plasma level of 8.8-12.4 mg/L)
Trial: 20299628
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) alone
Trial: 20299628
Drug: Placebo theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo theophylline capsules + inhaled placebo
Trial: 20299628
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with FP and theophylline
Trial: 16022206
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no weekly messages)
Trial: 1961958
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg (n = 40)
Trial: 1961958
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg/kg (n = 40)
Trial: 17224860
Drug: Isoflavone treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone treatment
Trial: 10980840
Drug: Direct thrombin
RxNorm normalized name: Direct thrombin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct thrombin inhibitors (hirudin, hirulog) as adjuncts to thrombolytic therapy
Trial: 10980840
Drug: Hirudin administered
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin administered at a mean of 34 and 50 minutes after thrombolytic therapy
Trial: 10980840
Drug: Direct thrombin
RxNorm normalized name: Direct thrombin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct thrombin inhibitors administered prior to thrombolysis
Trial: 7594905
Drug: Ritodrine hydrochloride
RxNorm normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritodrine hydrochloride infusion
Trial: 2183052
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with irradiation (27 Gy) of the involved field
Trial: 28339738
Drug: Tapering of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering of TNF inhibitors (TNFi)
Trial: 25588456
Drug: L-dopa (100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (100/25 mg of l-dopa/carbidopa daily)
Trial: 19835117
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus acupoint injection (Group C)
Trial: 19835117
Drug: Electroacupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture plus acupoint injection (Group D)
Trial: 17919229
Drug: Interferon and
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon and lamivudine combination therapy
Trial: 17919229
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon monotherapy
Trial: 17919229
Drug: Conventional interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional interferon monotherapy
Trial: 17919229
Drug: Conventional interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional interferon and lamivudine combination therapy
Trial: 7117677
Drug: Nabumetone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (1 g at night)
Trial: 371561
Drug: Naproxen (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (250 mg b.i.d.)
Trial: 28877841
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy for health anxiety (CBT-HA) - 4 to 10 sessions of 1-hour CBT-HA
Trial: 28877841
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy for health anxiety (CBT-HA)
Trial: 11264066
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam spray (4 mg)
Trial: 9681343
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% SDZ ASM 981 cream applied twice daily
Trial: 9681343
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% SDZ ASM 981 cream applied once daily
Trial: 25758624
Drug: 5% glucose-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose-containing intravenous solution (D5LR)
Trial: 16485727
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) treatment (1200 mg/day in 3 divided doses for 3 days followed by 300 mg i.v. after anaesthesia induction)
Trial: 16485727
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PTX treatment)
Trial: 10866882
Drug: tranexamic acid,
RxNorm normalized name: Tranexamic Acid, 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tranexamic acid, 10 mg. kg(‐1). h(‐1)
Trial: 10866882
Drug: epsilon‐aminocaproic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epsilon‐aminocaproic acid, 16 mg. kg(‐1). h(‐1)
Trial: 3092780
Drug: Alprazolam treatment
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam treatment in 8 patients
Trial: 24850615
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving weekly on-site lectures unrelated to exercise.
Trial: 22219220
Drug: Surinabant 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surinabant 2.5 mg/day
Trial: 22219220
Drug: Surinabant 5
RxNorm normalized name: Surinabant
DrugBank: Surinabant (DB13070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surinabant 5 mg/day
Trial: 22219220
Drug: Surinabant 10
RxNorm normalized name: Surinabant
DrugBank: Surinabant (DB13070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surinabant 10 mg/day
Trial: 18485010
Drug: Lower number
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower number of cells (10,000,000) in Group L, n = 13
Trial: 18485010
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cell treatment) in Group C, n = 17
Trial: 15769986
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (30 mug ethinyl estradiol and 150 mug levonorgestrel) for 9 months
Trial: 10406153
Drug: Defibrotide (800-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (800-1600 mg daily)
Trial: 2210618
Drug: human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human growth hormone (hGH) alone
Trial: 2210618
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy with oxandrolone
Trial: 6108555
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg i.v.
Trial: 6108555
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg i.v.
Trial: 20638139
Drug: Lip strengthening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lip strengthening exercises using an oral screen for 16 min, 5 days/week for 16 weeks.
Trial: 20638139
Drug: Lip strengthening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lip strengthening exercises using an oral screen.
Trial: 15508179
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with birch pollen extract
Trial: 17012870
Drug: Hexavalent combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent combined vaccine (DTaP‐IPV‐PRP approximately T‐HBs, HEXAVAC)
Trial: 18447898
Drug: Static night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static night splinting for six months worn at night time only, in addition to hand therapy.
Trial: 18447898
Drug: Hand therapy
RxNorm normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand therapy only (non-splint group).
Trial: 12593525
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) 800 microg day(‐1) suspension for nebulization
Trial: 10414911
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and GM-CSF
Trial: 31353989
Drug: nalbuphine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.07 mg/kg
Trial: 31353989
Drug: dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexmedetomidine 0.5 µg/kg
Trial: 29079057
Drug: Cold saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold saline irrigation (20 mL at 2.5°C for 5 minutes)
Trial: 1444945
Drug: EMLA 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 5% Cream
Trial: 22876438
Drug: Weifuchun tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weifuchun tablets
Trial: 20398351
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 gram by intravenous injection)
Trial: 18548827
Drug: Mirtazapine 7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 7.5, 15, 30, and/or 45 mg (Study 1)
Trial: 18548827
Drug: Mirtazapine 15
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg (Study 2)
Trial: 18548827
Drug: Mirtazapine 15
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg + Compound CD0012 (Study 2)
Trial: 16217274
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors and 4-hydroxytamoxifen
Trial: 10378706
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg daily)
Trial: 7712685
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg daily)
Trial: 6316518
Drug: Biostim (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostim (8 mg/day) for 15 days
Trial: 30971316
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of special medication (IV fluid, IV antibiotic, and blood transfusion)
Trial: 22243494
Drug: Warfarin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin + Anacetrapib
Trial: 19640014
Drug: Schema-Focused Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema-Focused Therapy (SFT)
Trial: 3988972
Drug: Ketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.25 mg/kg
Trial: 15815895
Drug: Cisatracurium infusion
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium infusion
Trial: 12444178
Drug: HPV‐16 virus‐like‐particle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐16 virus‐like‐particle vaccine (40 microg per dose)
Trial: 10349300
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of ethylcysteine (EC) for 3 months
Trial: 10349300
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of Vitamin E (Vit. E) for 3 months
Trial: 7173046
Drug: Codeine sulfate
RxNorm normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine sulfate 60 mg po
Trial: 7173046
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate 60 mg im
Trial: 29399865
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU cholecalciferol daily for 5 months
Trial: 8225149
Drug: Moxonidine (0.2-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.2-0.4 mg daily)
Trial: 23881862
Drug: 60-second-delayed therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-second-delayed therapy (arm C)
Trial: 23881862
Drug: Inappropriate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate therapy in diabetic patients
Trial: 23881862
Drug: Appropriate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate therapy in diabetic patients
Trial: 20827448
Drug: IR‐A irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR‐A irradiation treatment
Trial: 18005966
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C and E supplementation (343 mg and 84 mg respectively)
Trial: 16012275
Drug: Quetiapine dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine dosage escalation to 400 mg/d in 5 days
Trial: 16012275
Drug: Quetiapine dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine dosage escalation to 400 mg/d in 3 days
Trial: 16012275
Drug: Quetiapine dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine dosage escalation to 400 mg/d in 2 days
Trial: 9892331
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (500 mg twice daily)
Trial: 9892331
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (200 mg twice daily)
Trial: 29433500
Drug: Local neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local neck treatment
Trial: 29433500
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment plus tailored sensorimotor exercises
Trial: 29433500
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment plus balance exercises
Trial: 29433500
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment plus sensorimotor and balance exercises
Trial: 20647478
Drug: Neratinib (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (240 mg)
Trial: 20647478
Drug: Neratinib (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (240 mg) plus ketoconazole
Trial: 17582439
Drug: Intraspinal injections
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraspinal injections of autologous mesenchymal stem cells (MSCs) at the thoracic level
Trial: 17582439
Drug: Intraspinal injections
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraspinal injections of autologous mesenchymal stem cells (MSCs)
Trial: 11917904
Drug: Dihydrotestosterone (DHT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotestosterone (DHT; 70 mg/day) for 3 months
Trial: 11917904
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for 3 months
Trial: 7614103
Drug: Cisapride 30
RxNorm normalized name: cisapride 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 30 mg daily
Trial: 1978771
Drug: Clindamycin, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin, 600 mg intravenously every 6 hours, followed by oral clindamycin, 300 mg every 6 hours for a minimum of 4 weeks.
Trial: 1978771
Drug: Penicillin G,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin G, 2 million U every 4 hours for no less than 8 days, followed by oral penicillin V, 750 mg every 6 hours for a minimum of 4 weeks.
Trial: 31116996
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) + photodynamic therapy (PDT)
Trial: 28975543
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A and B vaccine injection (accelerated schedule)
Trial: 28975543
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B recombinant DNA vaccine (conventional schedule)
Trial: 25880756
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 1200 mg QD
Trial: 25880756
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 1600 mg QD
Trial: 23718748
Drug: Insulin (n=32)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (n=32)
Trial: 21262871
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg/day for 6 months
Trial: 18937965
Drug: Oral irreversible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irreversible P2Y12 receptor antagonists